Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy

Overview

Journal Drugs Real World Outcomes

Date 2019 Dec 19

PMID 31848905

Citations 15

Authors

Cristina Scavone

Cristina Di Mauro

Rosanna Ruggiero

Francesca Futura Bernardi

Ugo Trama

Maria Luisa Aiezza

Concetta Rafaniello

Annalisa Capuano

Affiliations

Soon will be listed here.

Abstract

Background: Allopurinol can induce severe cutaneous adverse reactions (SCARs), including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Aims And Methods: We analyzed the Individual Case Safety Reports (ICSRs) sent from January 2001 until April 2019 to the Campania regional Center of Pharmacovigilance (Southern Italy) that reported allopurinol as suspected, with a focus on those reporting at least one serious cutaneous adverse drug reaction (ADR). This study was aimed to describe the main characteristics of all ADRs associated with allopurinol, analyze the proportion of serious cutaneous ADRs of total ICSRs related to allopurinol and to compare the main features (age, sex, seriousness and outcome) of ICSRs that reported serious cutaneous ADRs with those that did not.

Results: The Campania regional Center of Pharmacovigilance received 108 ICSRs that reported allopurinol as suspected. ADRs occurred more frequently in the elderly (median age: 71 years) and female patients (53.7%). Fifty-seven percent of all ADRs were classified as serious and 58% had a favorable outcome. Fifty-six ICSRs reported at least one serious cutaneous ADR; among these ICSRs, 37 cases of SCARs were found [DRESS syndrome (n = 3; 5.4%), SJS (n = 8; 14.3%) and TEN (n = 26; 46.4%)]. Serious cutaneous ADRs commonly occurred in the elderly (median age: 73 years) and female patients (62.5%). They frequently required hospitalization (75%) and had an unfavorable outcome (46%). No statistically significant differences were found between ICSRs that reported serious cutaneous ADRs and ICSRs that did not report serious cutaneous ADRs except for the seriousness degree "Hospitalization or its prolongation" and the outcome degrees "Unfavorable" and "Favorable".

Conclusion: This study found that 52% (56/108) of all ICSRs having allopurinol as a suspected drug were serious cutaneous ADRs. Serious cutaneous ADRs associated with allopurinol frequently required hospitalization or prolonged hospitalization, and almost half had an unfavorable outcome.

Citing Articles

Is pancreatitis associated with meglumine antimoniate treatment for canine leishmaniosis? A multicentric prospective study.

Vineta C, Castro J, Lopez M, Frau M, Costas A, Arenas C Parasit Vectors. 2024; 17(1):532.

PMID: 39716313 PMC: 11665078. DOI: 10.1186/s13071-024-06617-7.

Stevens-Johnson Syndrome From Combined Allopurinol and Angiotensin-Converting Enzyme Inhibitors: A Narrative Review.

Fabian I, Maddox K, Robicheaux C, Islam R, Anwar A, Dorius B Cureus. 2024; 16(1):e51899.

PMID: 38333456 PMC: 10850002. DOI: 10.7759/cureus.51899.

Implementing HLA-B*58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors' and patients' perspective.

Ng W, Hussein N, Jenn Ng C, Qureshi N, Lee Y, Kwan Z PLoS One. 2024; 19(1):e0296498.

PMID: 38206925 PMC: 10783771. DOI: 10.1371/journal.pone.0296498.

Skin Toxicities Associated with Botulin Toxin Injection for Aesthetic Procedures: Data from the European Spontaneous Reporting System.

Nicoletti M, Anatriello A, Liguori V, Cantone A, Mauro G, Izzo I Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004476 PMC: 10675122. DOI: 10.3390/ph16111611.

Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database.

Nicoletti M, Crisci E, Cosenza V, Riccardi C, Campitiello M, Ruggiero D Drugs Real World Outcomes. 2023; 11(1):33-41.

PMID: 37907712 PMC: 10928059. DOI: 10.1007/s40801-023-00399-7.

References

Yang C, Chen C, Deng S, Huang C, Lin Y, Chen Y . Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan. JAMA Intern Med. 2015; 175(9):1550-7. DOI: 10.1001/jamainternmed.2015.3536. View

Sehgal V, Srivastava G . Toxic epidermal necrolysis (TEN) Lyell's syndrome. J Dermatolog Treat. 2006; 16(5-6):278-86. DOI: 10.1080/09546630500375684. View

Coutellier P, Delgrange B . [Fatal toxic epidermolysis following administration of allopurinol]. Acta Clin Belg. 1989; 44(3):196-8. View

Peter J, Lehloenya R, Dlamini S, Risma K, White K, Konvinse K . Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. J Allergy Clin Immunol Pract. 2017; 5(3):547-563. PMC: 5424615. DOI: 10.1016/j.jaip.2017.01.025. View

Atzori L, Pinna A, Mantovani L, Ferreli C, Pau M, Mulargia M . Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department--Cagliari University (Italy). J Eur Acad Dermatol Venereol. 2011; 26(11):1424-30. DOI: 10.1111/j.1468-3083.2011.04313.x. View

Arantes L, Reis C, Novaes A, Carvalho M, Gottems L, Novaes M . Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiological and clinical outcomes analysis in public hospitals. An Bras Dermatol. 2017; 92(5):661-667. PMC: 5674699. DOI: 10.1590/abd1806-4841.20176610. View

Qin T, Zhou X, Wang J, Wu X, Li Y, Wang L . Hyperuricemia and the Prognosis of Hypertensive Patients: A Systematic Review and Meta-Analysis. J Clin Hypertens (Greenwich). 2016; 18(12):1268-1278. PMC: 8031654. DOI: 10.1111/jch.12855. View

Kumari R, Timshina D, Thappa D . Drug hypersensitivity syndrome. Indian J Dermatol Venereol Leprol. 2011; 77(1):7-15. DOI: 10.4103/0378-6323.74964. View

Choi H, Soriano L, Zhang Y, Garcia Rodriguez L . Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012; 344:d8190. PMC: 3257215. DOI: 10.1136/bmj.d8190. View

10.

Lalosevic J, Nikolic M, Gajic-Veljic M, Skiljevic D, Medenica L . Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. Int J Dermatol. 2014; 54(8):978-84. DOI: 10.1111/ijd.12702. View

11.

Fritsch P, Sidoroff A . Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol. 2001; 1(6):349-60. DOI: 10.2165/00128071-200001060-00003. View

12.

Valeyrie-Allanore L, Sassolas B, Roujeau J . Drug-induced skin, nail and hair disorders. Drug Saf. 2007; 30(11):1011-30. DOI: 10.2165/00002018-200730110-00003. View

13.

Scavone C, Sportiello L, Sullo M, Ferrajolo C, Ruggiero R, Sessa M . Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. Front Pharmacol. 2017; 8:607. PMC: 5592230. DOI: 10.3389/fphar.2017.00607. View

14.

Inacio P, Cavaco A, Airaksinen M . The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2016; 83(2):227-246. PMC: 5237689. DOI: 10.1111/bcp.13098. View

15.

Wolfson A, Zhou L, Li Y, Phadke N, Chow O, Blumenthal K . Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module. J Allergy Clin Immunol Pract. 2018; 7(2):633-640. PMC: 6363826. DOI: 10.1016/j.jaip.2018.08.013. View

16.

Tsai T, Yeh T . Allopurinol in dermatology. Am J Clin Dermatol. 2010; 11(4):225-32. DOI: 10.2165/11533190-000000000-00000. View

17.

Fang B, Song Y, Ma J, Zhao R . Severe epidermal necrolysis after bortezomib treatment for multiple myeloma. Acta Haematol. 2007; 118(2):65-7. DOI: 10.1159/000102604. View

18.

Thong B, Tan T . Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011; 71(5):684-700. PMC: 3093074. DOI: 10.1111/j.1365-2125.2010.03774.x. View

19.

Ramasamy S, Korb-Wells C, Kannangara D, Smith M, Wang N, Roberts D . Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf. 2013; 36(10):953-80. DOI: 10.1007/s40264-013-0084-0. View

20.

Menter T, Tzankov A . Drug Reaction, Eosinophilia, and Systemic Symptoms (DRESS) syndrome associated with allopurinol leading to acute necrotizing eosinophilic myocarditis and death due to papillary muscle rupture. J Allergy Clin Immunol Pract. 2016; 4(6):1262-1264. DOI: 10.1016/j.jaip.2016.07.005. View